世卫组织2023 年扩大免疫计划 (-EPI)- 资料表：东帝汶

Year

Milestone

1978

2000

2007

2012

2016

2016

2016

2016

2016

2016

2019

EPIstarted

EPIre-structuredinMarch

DTP-HepBvaccineintroduced

DTP-Hib-HepBvaccineintroduced

MRvaccineintroducedinFeb

SeconddoseofMRintroducedinFeb

HepBbirthdoseintroducedinFeb

DPT/DTvaccine(boosterdose)introducedinFeb

IPVintroducedinFeb

tOPVtobOPVswitchedon18April

RotavirusvaccineintroducedinDec

Source:cMYP2016-2022andEPI/MOH

Disclaimer:Theboundariesandnames

shownandthedesignationsusedonallthemapsdonotimply

theexpressionofanyopinion

whatsoeveronthepartofthe

WorldHealthOrganization

concerningthelegalstatusofanycountry,territory,cityorareaorofitsauthorities,orconcerning

thedelimitationofitsfrontiersorboundaries.

FACTSHEET2023

TIMORLESTE

EXPANDEDPROGRAMMEONIMMUNIZATION(EPI)

Table1:EPIHistory

Table2:Basicinformation2022

Totalpopulation1

Livebirths1

Children<1year1

Children<5years1

Children<15years1

Pregnantwomen1

WCBA1(15-49years)

Neonatalmortalityrate2

Infantmortalityrate2

Under-fivemortalityrate2

Maternalmortalityratio2

Division/Province/State/Region

Municipality

Postos/Sub-district

Sucos/Village

Populationdensity1(persq.km)

Populationlivinginurbanareas2

Populationusingatleastbasicdrinking-waterservices2

Populationusingatleastbasicsanitationservices2

Totalexpenditureonhealthas%ofGDP2BirthsattendedbyskilledhealthpersonnelNeonatesprotectedatbirthagainstNT2Childrennotcoveredbyimmunization

programme(zerodosechildren)3

1,318,445

31,832

31,832

157,324

474,368

36,586

332,107

22.23(per1,000LB)43.08(per1,000LB)50.55(per1,000LB)204(per100,000LB)

13

13

72

452

89

35.80%

87%

58%

5.45%

57%

83%

4,184

1SEARannualEPIreportingform,2022

2WHO,GlobalHealthObservatory(GHO)data

/gho/dataaccessedon03August2023

3DTP1coveragefromWHOandUNICEFestimatesof

immunizationcoverageandUNestimatedunderonepopulation

Figure1:Nationalimmunizationcoverage,2013-2022

Source:WHOandUNICEFestimatesofimmunizationcoverage

Table3:Immunizationschedule,2022

Vaccine

Ageofadministration

BCG

HepB

DTP-Hib-HepB

OPV

IPV

MR

Td

DT

DTP

Rotavirus

VitaminA

Birth

Birthwithin24hours

6weeks,10weeksand14weeks

Birth,6weeks,10weeksand14weeks

14weeks

9monthsand18months

Females15to49years(1stpregnancycontact,+1months,+6months,

+1year,+1year)

6years

18months

6weeks,10weeksand14weeks

6-36months(with6monthsinterval)

Source:WHO/UNICEFJRF,2022

Table4:Immunizationsystemhighlights

cMYPforimmunization

NITAG-TL

Spendingonvaccinesfinancedbythegovernment

Spendingonroutine

immunizationprogrammefinancedbythegovernment

Updatedmicro-plansthatincludeactivitiestoimproveimmunizationcoverage

Nationalpolicyforhealthcarewastemanagementincludingwastefromimmunization

activities

NationalsystemtomonitorAEFI

MostrecentEPICES

>80%coverageforDTP-Hib-HepB3

>90%coverageforMCV1

>90%coverageforMCV2

>10%drop-outrateforDTP-Hib-HepB1toDTP-Hib-HepB3

2016-2022

fullyfunctional

100%

64%

13districts(100%)

inplace

inplace

EPICoveragesurvey2018

13districts(100%)

5districts(38%)

4districts(31%)

5districts(36%)

Source:WHO/UNICEFJRF,2022

WorldHealthOrganization•SEARO/CDS/IVD•31October2023

Figure2:DTP3coverage1,diphtheriaandpertussiscases2,1980-2022

Figure3:TT2+coverage1andNTcases2,1980-2022

1

2

WHOandUNICEFestimatesofimmunizationcoverage

WHOvaccine-preventablediseases:monitoringsystem2022

1Countryofficialestimates,1980-2022

2WHOvaccine-preventablediseases:monitoringsystem2022

DTP-Hib-HepB3coveragebydistrict

Figure4:2021

Figure5:2022

<70%70%-79%80%-89%>90%

Source:SEARannualEPIreportingform,2021and2022(administrativedata)

Table5:Reportedcasesofvaccinepreventablediseases,2016-2022

Year

Polio

Diphtheria

Pertussis

NT(%ofall

tetanus)

Measles

Rubella

Mumps

JE

CRS

2016

0

0

6

0

2

8

0

1

0

2017

0

0

1

1(100%)

0

3

21

7

0

2018

0

0

0

1(100%)

0

8

26

0

0

2019

0

0

7

0

22*

21

ND

23

0

2020

0

0

5

2(100%)

2

5

0

0

0

2021

0

0

0

ND

3

4

0

ND

0

2022

0

0

0

1(50%)

8

41

0

1

0

Source:WHO/UNICEFJRF(multipleyears)*Imported/ImportrelatedND=Nodata

Table6:AFPsurveillanceperformanceindicators,2016-2022

•ThelastlaboratoryconfirmedpoliocaseduetoWPVwasreportedinNovember1993

Indicator

2016

2017

2018

2019

2020

2021

2022

AFPcases

10

5

0

5

1

0

0

Wildpoliovirusconfirmedcases

0

0

-

0

0

-

-

Compatiblecases

0

0

-

0

0

-

-

Non-polioAFPrate1

2.16

1.08

-

0.83

0.21

-

-

Adequatestoolspecimencollectionpercentage2

0.5

60%

-

0.2

0%

-

-

Totalstoolsamplescollected

-

8

-

2

1

-

-

%NPEVisolation

-

13

-

0

0

-

-

%Timelinessofprimaryresultreported3

-

100

-

100

100

-

-

1NumberofdiscardedAFPcasesper100,000childrenunder15yearsofage.

2Percentwith2specimens,24hoursapartandwithin14daysofparalysisonset.

3Resultsreportedwithin14daysofsamplereceivedatlaboratory.

Non-polioAFPratebydistrict

Figure6:2021

Adequatestoolspecimencollection%bydistrict

Figure8:2021

NoAFPcasereported

NoAFPcasereported

Figure7:2022

Figure9:2022

NoAFPcasereported

NoAFPcasereported

<11–1.99>2Nonon-polioAFPcase<60%60%-79%>80%NoAFP

Table7:OPVSIAs

Year

Antigen

Geographiccoverage

Targetage

Targetpopulation

Coverage(%)

Round1

Round2

Round1

Round2

2005

2015*

2018*

2020

OPV

OPV

OPV

OPV

NID

NID

NID

<5

<5

<5

years

years

years

177,713

522,943

165,013

93

96

111

-

102

-

-

-

Source:WHO/UNICEFJRF(multipleyears)

VACCINESPROTECT

SUSTAIN.ACCELERATE.INNOVATE.

Figure10:HepB3andHepBbirthdoseimmunizationcoverage1,2000-2022

Figure11:MCV1&MCV2coverage1andmeasles,rubellacases2,1980-2022

1

WHOandUNICEFestimatesofimmunizationcoverage

1WHOandUNICEFestimatesofimmunizationcoverage

2WHOvaccine-preventablediseases:monitoringsystem2022

MR1coveragebydistrict

MR2coveragebydistrict

Figure12:2021

Figure14:2021

Figure13:2022

Figure15:2022

<80%80%-89%90%-94%>95%

Source:SEARannualEPIreportingform,2021and2022(administrativedata)

Table8:MCV/MRSIAs

Year

Antigen

Geographiccoverage

Targetgroup

Target

Coverage%

2003

M

nationwide

9to59months

128,318

99

2006

M

nationwide

6monthsto14years

390,687

40

2009

M

nationwide

9to59months

167,136

76

2011

M

nationwide

6monthsto14years

494,427

92

2015

MR

nationwide

6monthsto14years

501,832

97

2018

MR

nationwide

6to59months

142,935

110

Source:WHO/UNICEFJRF(multipleyears)

WorldHealthOrganization•SEARO/CDS/IVD•31October2023

Figure16:Immunityagainstmeasles-immunityprofilebyagein2022*

*ModelledusingMSPtoolver2

Figure17:Immunityagainstrubellathroughvaccination-immunityprofilebyagein2022*

*ModelledusingWHOandUNICEFestimatesandJRF(multipleyears)anddoesnotincludeimmunityduetonaturalinfection

Figure18:Confirmedmeaslescases*bymonth2020-2022

*Includeslaboratoryconfirmed,epidemiologicallylinkedandclinicallycompatiblecasesSource:SEARmeaslescase-baseddata

Figure19:Confirmedrubellacases*bymonth2020-2022

*Includeslaboratoryconfirmedandepidemiologicallylinkedcases

Source:SEARmeaslescase-baseddata

andimmunizationmedicalofficersandlaboratories

NationalHealthLaboratory,Dili

•Nationalmeaslesandrubellalaboratory

•NationalJapaneseencephalitislaboratory

VACCINESPROTECT

SUSTAIN.ACCELERATE.INNOVATE.

Figure20:Vaccinationstatusofconfirmed(laboratory,Epilinkedandclinicallycompatible)measlescases,byagein2021and2022

Source:SEARmeaslescase-baseddata

Figure21:Vaccinationstatusofconfirmed(laboratoryandEpilinked)rubellacases,byagein2021and2022

Source:SEARmeaslescase-baseddata

Table9:Summaryofmeaslessurveillanceindicators,2020-2022

Figure22:NetworkofWHOsupportedsurveillance

Indicator

Target

2020

2021

2022

Numberofsuspectedmeaslescases

109

43

47

Confirmedmeaslescases

0

4

3

0

Labconfirmed

0

0

0

0

Epi-Linked

0

0

0

0

Clinically-compatible

0

4

3

0

Confirmedrubellacases

0

5

4

0

Labconfirmed

0

5

2

0

Epi-Linked

0

0

2

0

Discardednon-measlesnon-rubellacases

100

38

47

Percentageofsuspectedcaseswithadequateinvestigationinitiatedwithin48hoursofnotification

≥80%

ND

100

100

Reportingrateofnon-measlesnon-rubellacasestonationallevelper100,000population

≥2

ND

0.83

6.1

Percentageofsecond-leveladministrativeunitsreportingat